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doi:10.1016/j.fjs.2011.08.014Summary Treatment of tracheoesophageal (TE) fistula is always a challenge, in particular TE
fistula caused by malignancy. In the past decade, the development of a self-expanding metal
stent (SEMS) has made management of esophageal stenosis or perforation much easier. Never-
theless, management of a cervical esophageal lesion is still debatable. A cervical esophageal
stent may compromise the upper esophageal sphincter (UES) function and is usually listed as
a contraindication. Here, a 53-year-old male had cervical esophageal cancer complicated with
a TE fistula. After initial management with a SEMS, the patient had temporary improvement,
but later suffered a recurrent TE fistula. The TE fistula was successfully managed by the place-
ment of a second modified SEMS just below the UES without removal of the previous SEMS. The
patient tolerated the procedure well and regained proper swallowing function.
Copyright ª 2011, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Tumors in the cervical portion of the esophagus account for
7e10% of all esophageal cancers.1 Tracheoesophageal (TE)of Thoracic Surgery, Chi-Mei
d, Yung Kang City, Tainan,
.hinet.net, bkducky@gmail.
ight ª 2011, Taiwan Surgical Assofistula occurs in approximately 5e15% of patients with
esophageal cancer.1 Esophageal stents in this area have
traditionally been considered to be contraindicated. An
increased risk of perforation, pulmonary aspiration [by
compromising upper esophageal sphincter (UES) function],
migration of the prosthesis into the hypopharynx, and an
intolerable foreign body sensation, are general concerns.1,2
Although a cervical esophageal lesion can be successfully
managed by placement of a Polyflex stent across the UES
temporarily without major complications,3 avoidance ofciation. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 2 A modified SEMS with a 7-mm length funnel shape
proximal end and a diameter of 18 mm. The length of the stent
is 12 cm. It is a subtype of Choostent invented by Dr Shim.
Cervical TE fistula treated with a modified SEMS 197a permanent esophageal stent across the UES is generally
agreed upon. We report a patient with TE fistula recurrence
after stenting. He was treated successfully with a modified
self-expanding metal stent (SEMS) in addition to a previous
SEMS.
2. Case report
A 53-year-old male presented to our hospital for progressive
cough and dysphagia in the past month. The patient had no
history of systemic diseases but reported habitual use of
alcohol, cigarettes, and betel nuts for more than 20 years.
No body weight loss was noted. Physical examination failed
to show specific findings. Chest computed tomography (CT)
was suggestive of cancer in the upper 1/3 of the esophagus.
Panendoscopy revealed an infiltrative tumor, located at
20e25 cm from the incisor. Biopsy of the tumor showed
squamous cell carcinoma (SCC). Bronchoscopy revealed
direct invasion of the trachea by the tumor.
A diagnosis of locally advanced SCC of the esophagus,
upper 1/3, stage III, T4N1M0, was made according to the
American Joint Committee Cancer classification system.
Concurrent chemoradiation therapy was suggested accord-
ing to the National Comprehensive Cancer Network guide-
line. A feeding tube was not used because the patient was
still capable of oral intake.
One course of cisplatin combined with 5-FU at the
outpatient department was administered. Radiation
therapy at a dose of 5000 cGy was also started.
One month later, the patient complained of severe
postprandial cough. Body weight loss of more than 2 kg was
also reported. Bronchoscopy and esophagography were
performed and a TE fistula was found. Owing to this clinical
condition, a SEMS was inserted to stop airway contamina-
tion. Esophagography demonstrated adequate blockage of
the TE fistula.
One month later, severe cough recurred. A plain chest
film X-ray showed pneumonia. In view of the patient’s
previous history, chest CT, esophagography and bronchos-
copy (Fig. 1A) were performed to confirm TE fistulaFigure 1 (A) Bronchoscopic view of the TE fistula. The proxima
Bronchoscopic view of the TE fistula after placement of a modified
TE fistula properly.recurrence. The images revealed a TE fistula proximal to
the previous SEMS. The new TE fistula was located at 20 cm
from the incisor, which was rather close to the upper
esophageal sphincter (UES). Considering that retraction of
the first SEMS might cause further extension of the TE
fistula, we did not remove the stent. Instead, we deployed
another modified SEMS with a smaller funnel-shape prox-
imal end (Fig. 2). The proximal end of the new SEMS was
placed at 17 cm from the incisor.
After deployment of the second SEMS, esophagography
(Fig. 3) and bronchoscopy (Fig. 1B) were performed again
and showed no signs of TE fistula recurrence. The patient
complained of neck pain, but the patient became capable
of oral intake again. The patient died 4 months after
placement of the second SEMS due to cancer progression.
3. Discussion
A SEMS is a common choice for patients with unresectable
middle and distal esophageal cancer to facilitate oral
intake. Deployment of SEMS is easy and complications are
few.1 The associated discomfort, migration rate, and peri-
operative risk are much lower than with silicon models.1,4,5l boundary of the first SEMS was visible via the TE fistula. (B)
SEMS. The second SEMS is seen via the TE fistula and sealed the
Figure 3 Esophagography following insertion of the second
SEMS. There was no more barium leakage into the respiratory
tract.
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Traditionally, a SEMS has a membrane-covered central
segment and a symmetrical larger diameter bared surface
at both ends. In our hospital, we usually choose a Niti-S
stent or Choostent, for which it is easier to readjust the
stent position after deployment.
Traditionally, a SEMS in the cervical esophagus was
regarded as a contraindication, because the larger diam-
eter end may cause UES dysfunction and discomfort. To
overcome this, Dr Shim modified the SEMS with a smaller
diameter funnel-shape proximal end.1,2 In comparison with
the standard SEMS, it has a shorter length of the proximal
funnel (7 mm vs. 20 mm) and a narrower fully expanded
diameter (18 mm vs. 20 mm). The modification decreases
UES compromise and foreign body sensation.2
Our patient was treated first with a Niti-S stent because
there was no modified SEMS available in Taiwan. The
proximal end of the SEMS was placed at 20 cm from the
incisor and achieved successful coverage of the TE fistula
initially. However, it could not be determined how far theproximal end of the SEMS exceeded the proximal end of the
TE fistula.
The cause of recurrence was not certain, but three
possibilities were considered. First, mild migration of the
SEMS caused by tumor shrinkage after concurrent chemo-
radiation therapy (CCRT). Second, additional pressure due
to the larger diameter of the SEMS proximal end causing
further tear of the TE fistula. Third, further shortening of
the SEMS when it expanded to its full width after place-
ment. One or a combination of these factors may have
contributed to stent failure.
Retraction of the first SEMS with panendoscopy was
initially contemplated, but considering that there was
a high risk of further tear it was not attempted. Instead, we
decided to place a second stent to cover the lesion.
However, a traditional SEMS could have compromised the
UES and thus we asked the stent company to help us obtain
a modified stent.
We chose a modified SEMS (Choostent, modified by Shim
et al) to accomplish the task.1,2 The proximal end was
placed at 17 cm from the incisor, where cricoids were
visible on fluoroscopy. Panendoscopy showed its proximal
end just beneath the UES. Postprandial cough was relieved
after placement of the second SEMS. No major complica-
tions occurred, and foreign body sensation was tolerable.
With this experience, it is now considered acceptable to
place a modified SEMS just beneath the UES.
4. Conclusions
We conclude that cervical SEMS placement is practical with
a modified SEMS. However, the proximal end of the SEMS
should not exceed the UES. In addition, a new SEMS resting
on a previous SEMS is acceptable. Further studies are
needed to determine the adequate gap between the UES
and SEMS. It is also important to develop a method to
determine the position of the implanted SEMS.
References
1. Shim CS. Esophageal stenting in unusual situations. Endoscopy.
2003;35:514e518.
2. Shim CS, Jung IS, Bhandari S, et al. Management of malignant
strictures of the cervical esophagus with a newly-designed self-
expanding metal stent. Endoscopy. 2004;36:554e557.
3. Buscaglia JM, Sherwood JT, Jagannath SB. Endoscopic treat-
ment of a cervical esophageal dissection using a Polyflex self-
expanding plastic stent. Prac Gastroenterol. 2007;31:68e71.
4. Okamoto K, Shimizu T, Ichikawa D, et al. A case report of
esophageal cancer with tracheoesophageal fistula e improving
the quality of life by using a covered self-expandable metallic
stent. Gan To Kagaku Ryoho. 2005;32:1873e1874 [in Japanese].
5. Macdonald S, Edwards RD, Moss JG. Patient tolerance of cervical
esophageal metallic stents. J Vasc Interv Radiol. 2000;11:
891e898.
